[
  {
    "ts": null,
    "headline": "Beam Therapeutics: A Slow-Developing Story",
    "summary": "Beam Therapeutics' base editing tech shows promise in sickle cell & AATD.",
    "url": "https://finnhub.io/api/news?id=5669c6603a4581cb3a47182464b01980192c8fe0b301f23507140e511a6604c8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755427830,
      "headline": "Beam Therapeutics: A Slow-Developing Story",
      "id": 136399882,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160060870/image_1160060870.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Beam Therapeutics' base editing tech shows promise in sickle cell & AATD.",
      "url": "https://finnhub.io/api/news?id=5669c6603a4581cb3a47182464b01980192c8fe0b301f23507140e511a6604c8"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Most Undervalued Value Stocks to Buy Now. On August 12, 2025, Merck & Co., Inc. (NYSE:MRK) announced an update regarding its Phase 3 KEYNOTE-905 trial. According to the update, the trial met its primary and key secondary endpoints in patients with muscle-invasive […]",
    "url": "https://finnhub.io/api/news?id=a48e5e746aeace32d093c50284cdc32e4b2b07862cb94bbcff2c5a43a31fe6f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755412241,
      "headline": "Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial",
      "id": 136408501,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Most Undervalued Value Stocks to Buy Now. On August 12, 2025, Merck & Co., Inc. (NYSE:MRK) announced an update regarding its Phase 3 KEYNOTE-905 trial. According to the update, the trial met its primary and key secondary endpoints in patients with muscle-invasive […]",
      "url": "https://finnhub.io/api/news?id=a48e5e746aeace32d093c50284cdc32e4b2b07862cb94bbcff2c5a43a31fe6f0"
    }
  },
  {
    "ts": null,
    "headline": "Citi Raises PT on Pfizer Inc. (PFE) to $26; Maintains ‘Neutral’ Rating",
    "summary": "With strong hedge fund interest and a low price-to-earnings ratio, Pfizer Inc. (NYSE:PFE) secures a place on our list of the 10 Most Undervalued Value Stocks to Buy Now. Following the company’s strong Q2 performance, Citi raised its price target on Pfizer Inc. (NYSE:PFE) from $25 to $26 on August 6, 2025, maintaining a ‘Neutral’ […]",
    "url": "https://finnhub.io/api/news?id=339721c7f4e3c6440857653af9951f41c27c25d054a1db12c093c54d9fa0d4f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755412126,
      "headline": "Citi Raises PT on Pfizer Inc. (PFE) to $26; Maintains ‘Neutral’ Rating",
      "id": 136408652,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "With strong hedge fund interest and a low price-to-earnings ratio, Pfizer Inc. (NYSE:PFE) secures a place on our list of the 10 Most Undervalued Value Stocks to Buy Now. Following the company’s strong Q2 performance, Citi raised its price target on Pfizer Inc. (NYSE:PFE) from $25 to $26 on August 6, 2025, maintaining a ‘Neutral’ […]",
      "url": "https://finnhub.io/api/news?id=339721c7f4e3c6440857653af9951f41c27c25d054a1db12c093c54d9fa0d4f6"
    }
  }
]